Lean Rybelsus when…
- Needle anxiety would cost you consistency — a daily tablet removes the barrier
- You can keep Rybelsus's empty-stomach morning ritual
- You and your clinician are starting with oral semaglutide for type 2 diabetes
HEAD TO HEAD
Oral vs Injectable GLP-1.
Oral GLP-1s include Rybelsus (oral semaglutide, daily empty-stomach ritual) and Foundayo (orforglipron, a daily tablet with no empty-stomach rule, FDA-approved 1 April 2026). The worked example below is Rybelsus versus Wegovy — each column is that medicine's own label. Foundayo is a different molecule, manufacturer, indication, and dose schedule, so it has its own table. Weekly injectables still lead average trial outcomes; Ozempic, Zepbound, and Mounjaro each have their own tracker pages. The right form is the one you'll actually stay consistent with.
4.8★ · 3,200+ ratings on the App Store and Google Play
Education only, from FDA labels and published trials — never medical advice. Which medication is right for you is a decision for you and your clinician.
VERIFIEDGLP AIOral vs Injectable GLP-1Sources verified September 9, 2026
Free to tryCancel anytime
4.8★3,200+ ratings
iPhone + AndroidApp Store + Google Play
Either oneGLP AI tracks both — shots or pills
FDA-labeledFacts from prescribing information, cited
One timelineDoses · meals · symptoms · levels
AT A GLANCE
When each one makes sense.
Lean Wegovy when…
- You'd rather think about medication once a week than every morning
- Wegovy's weight-management indication and STEP-1 average outcomes matter for your goals
- A weekly shot is less friction for you than remembering a daily tablet
Lean Foundayo when…
- You want a daily tablet without Rybelsus's empty-stomach window
- Needle anxiety would cost you consistency
- Your clinician is considering Foundayo's weight-management indication
These are talking points for a clinician conversation, not a prescription.
SIDE BY SIDE
Rybelsus vs Wegovy, feature by feature.
| Rybelsus | Wegovy | |
|---|---|---|
| Active ingredient | semaglutide (oral) | semaglutide |
| Manufacturer | Novo Nordisk | Novo Nordisk |
| FDA approval | FDA-approved for type 2 diabetes | FDA-approved for chronic weight management |
| Form & frequency | Oral pill, daily | Injection, weekly |
| Dose range | 3 mg → 14 mg | 0.25 mg → 2.4 mg |
| Half-life | ~7 days | ~7 days |
| Headline trial result | A1C reductions up to 1.4% at 14 mg in the PIONEER program | Up to 14.9% mean body-weight reduction at 68 weeks (semaglutide 2.4 mg) |
| Most common side effect | Nausea (20% (14 mg)) | Nausea (44%) |
| Tracked by GLP AI | ✅ Doses, meals, side effects, levels | ✅ Doses, meals, side effects, levels |
Sources: Rybelsus Prescribing Information (Novo Nordisk) · Wegovy Prescribing Information (Novo Nordisk) · trials as cited on each medication's page.
FOUNDAYO
Foundayo (orforglipron), its own label.
Foundayo is not oral semaglutide. The rows below come from the FDA announcement and Foundayo prescribing information — not from the Rybelsus column above.
| Foundayo | |
|---|---|
| Brand / ingredient | Foundayo (orforglipron) |
| Manufacturer | Eli Lilly |
| FDA approval | FDA approved Foundayo (orforglipron) on 1 April 2026 for adults with obesity, or adults with overweight plus at least one weight-related comorbid condition, used with a reduced-calorie diet and increased physical activity |
| Form & frequency | Daily oral tablet — taken any time of day, no empty-stomach rule |
| Dose range | 0.8 mg → 17.2 mg (approved schedule, not the ATTAIN-1 36 mg trial dose) |
| Headline trial result | ATTAIN-1 reported about 12.4% mean weight loss at 72 weeks on the highest trial dose (36 mg daily). That trial dose is not the approved Foundayo schedule. |
| Tracked by GLP AI | Custom medication today — doses, meals, symptoms, and weight. Dedicated dose schedule and medication level chart still coming. |
Sources: FDA approval announcement — Foundayo (orforglipron), 1 April 2026 · Foundayo (orforglipron) Prescribing Information · Phase 2 obesity trial — Wharton et al., NEJM 2023 · ATTAIN-1 Phase 3 trial record (ClinicalTrials.gov) (Foundayo PI).
WHICHEVER YOU CHOOSE
Track either with GLP AI.
Rybelsus and Wegovy: doses (pills or shots), a 0–100 GLP-1 Meal Score for every meal, side effects beside dose days, and an estimated medication level chart. Foundayo: custom medication tracking today for doses, meals, symptoms, and weight — dedicated schedules and the level chart still coming.
THE QUICK ANSWERS
Oral vs Injectable GLP-1 — FAQs.
What is the difference between Rybelsus and Wegovy?+
Oral GLP-1s include Rybelsus (oral semaglutide, daily empty-stomach ritual) and Foundayo (orforglipron, a daily tablet with no empty-stomach rule, FDA-approved 1 April 2026). The worked example below is Rybelsus versus Wegovy — each column is that medicine's own label. Foundayo is a different molecule, manufacturer, indication, and dose schedule, so it has its own table. Weekly injectables still lead average trial outcomes; Ozempic, Zepbound, and Mounjaro each have their own tracker pages. The right form is the one you'll actually stay consistent with.
How are Rybelsus and Wegovy dosed?+
Rybelsus: 3 mg → 7 mg → 14 mg, daily (oral). Wegovy: 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg, weekly (injection). Escalation schedules come from each FDA label; your prescriber sets the pace.
How long do Rybelsus and Wegovy stay in your system?+
Rybelsus (semaglutide (oral)) has a ~7 days half-life; Wegovy (semaglutide) has a ~7 days half-life. That difference shapes dosing frequency and how missed doses feel — GLP AI's medication level chart visualizes both.
Which has more side effects — Rybelsus or Wegovy?+
Both are GI-first. Rybelsus's label lists nausea at 20% (14 mg); Wegovy's lists nausea at 44%. Cross-trial numbers aren't directly comparable, and individual tolerance varies — tracking your own timeline is more useful than comparing labels.
Can I switch between Rybelsus and Wegovy?+
Switching between GLP-1 medications is common and is entirely a decision for your prescriber, who will map an equivalent starting dose. A tracked history — doses, side effects, weight — makes that conversation concrete.
Which is right for me — Rybelsus or Wegovy?+
That's a clinical decision based on your health history, goals, tolerance, and coverage. This page is education, not medical advice. Whichever you and your clinician choose, GLP AI tracks it.
How do I track Rybelsus or Wegovy?+
GLP AI tracks both: doses (shots or pills), a 0–100 GLP-1 Meal Score for every meal, side effects beside dose days, and an estimated medication level chart — one timeline either way.
How is Foundayo different from Rybelsus?+
Both are daily oral GLP-1s. Rybelsus is oral semaglutide (Novo Nordisk), FDA-approved for type 2 diabetes, 3 mg → 14 mg, with an empty-stomach rule. Foundayo is orforglipron (Eli Lilly), FDA-approved 1 April 2026 for weight reduction, 0.8 mg → 17.2 mg, with no empty-stomach rule. See the Foundayo table on this page and the Foundayo tracker. GLP AI logs both as pills; Foundayo uses custom medication tracking until dedicated dose schedules and the level chart land.
Are more oral GLP-1s coming?+
Foundayo (orforglipron) is already FDA-approved (1 April 2026) as a daily tablet that does not require an empty stomach. Rybelsus remains the approved oral semaglutide option, with its morning ritual. Other oral programs may still be in trials.
Is a daily pill easier to stay consistent with than a weekly shot?+
It depends on you. Daily pills build a routine but give you 7 chances a week to slip; weekly shots are one decision but easier to forget entirely. GLP AI's reminders handle both. For Rybelsus and Wegovy, the medication level chart shows what a missed dose does. Foundayo tracking today is custom (doses, meals, symptoms, weight) without a first-class chart yet.
What about Ozempic, Zepbound, and Mounjaro?+
They are weekly injectables with their own labels — not the same as Wegovy. Ozempic and Mounjaro are approved for type 2 diabetes; Zepbound is tirzepatide for weight management. Use each medicine's tracker page for that label's data.
KEEP EXPLORING
Go further with GLP AI.
Track it once. Understand it forever.
Whichever medication wins, GLP AI tracks it — free to start.